139 related articles for article (PubMed ID: 22876881)
21. Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold.
Herberich B; Cao GQ; Chakrabarti PP; Falsey JR; Pettus L; Rzasa RM; Reed AB; Reichelt A; Sham K; Thaman M; Wurz RP; Xu S; Zhang D; Hsieh F; Lee MR; Syed R; Li V; Grosfeld D; Plant MH; Henkle B; Sherman L; Middleton S; Wong LM; Tasker AS
J Med Chem; 2008 Oct; 51(20):6271-9. PubMed ID: 18817365
[TBL] [Abstract][Full Text] [Related]
22. Discovery of new aminopyrimidine-based phosphoinositide 3-kinase beta (PI3Kβ) inhibitors with selectivity over PI3Kα.
Kim J; Hong S; Hong S
Bioorg Med Chem Lett; 2011 Dec; 21(23):6977-81. PubMed ID: 22030027
[TBL] [Abstract][Full Text] [Related]
23. Development of phosphocellulose paper-based screening of inhibitors of lipid kinases: case study with PI3Kβ.
Yanamandra M; Kole L; Giri A; Mitra S
Anal Biochem; 2014 Mar; 449():132-8. PubMed ID: 24380788
[TBL] [Abstract][Full Text] [Related]
24. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
Chang KY; Tsai SY; Wu CM; Yen CJ; Chuang BF; Chang JY
Clin Cancer Res; 2011 Nov; 17(22):7116-26. PubMed ID: 21976531
[TBL] [Abstract][Full Text] [Related]
25. Selective and potent small-molecule inhibitors of PI3Ks.
Jeong Y; Kwon D; Hong S
Future Med Chem; 2014 May; 6(7):737-56. PubMed ID: 24941870
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of PI3Kβ-selective inhibition revealed by reciprocal mutagenesis.
Zheng Z; Miller MS; Jennings IG; Thompson PE
ACS Chem Biol; 2013 Apr; 8(4):679-83. PubMed ID: 23360067
[TBL] [Abstract][Full Text] [Related]
27. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
[TBL] [Abstract][Full Text] [Related]
28. Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors.
Liu KK; Huang X; Bagrodia S; Chen JH; Greasley S; Cheng H; Sun S; Knighton D; Rodgers C; Rafidi K; Zou A; Xiao J; Yan S
Bioorg Med Chem Lett; 2011 Feb; 21(4):1270-4. PubMed ID: 21269826
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases.
Nishiguchi GA; Atallah G; Bellamacina C; Burger MT; Ding Y; Feucht PH; Garcia PD; Han W; Klivansky L; Lindvall M
Bioorg Med Chem Lett; 2011 Nov; 21(21):6366-9. PubMed ID: 21945284
[TBL] [Abstract][Full Text] [Related]
30. Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856.
Perreault S; Chandrasekhar J; Cui ZH; Evarts J; Hao J; Kaplan JA; Kashishian A; Keegan KS; Kenney T; Koditek D; Lad L; Lepist EI; McGrath ME; Patel L; Phillips B; Therrien J; Treiberg J; Yahiaoui A; Phillips G
J Med Chem; 2017 Feb; 60(4):1555-1567. PubMed ID: 28106991
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours.
Barlaam B; Cosulich S; Degorce S; Ellston R; Fitzek M; Green S; Hancox U; Lambert-van der Brempt C; Lohmann JJ; Maudet M; Morgentin R; Plé P; Ward L; Warin N
Bioorg Med Chem Lett; 2017 May; 27(9):1949-1954. PubMed ID: 28347666
[TBL] [Abstract][Full Text] [Related]
32. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
Kendall JD; O'Connor PD; Marshall AJ; Frédérick R; Marshall ES; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):69-85. PubMed ID: 22177405
[TBL] [Abstract][Full Text] [Related]
33. Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.
Certal V; Halley F; Virone-Oddos A; Delorme C; Karlsson A; Rak A; Thompson F; Filoche-Rommé B; El-Ahmad Y; Carry JC; Abecassis PY; Lejeune P; Vincent L; Bonnevaux H; Nicolas JP; Bertrand T; Marquette JP; Michot N; Benard T; Below P; Vade I; Chatreaux F; Lebourg G; Pilorge F; Angouillant-Boniface O; Louboutin A; Lengauer C; Schio L
J Med Chem; 2012 May; 55(10):4788-805. PubMed ID: 22524426
[TBL] [Abstract][Full Text] [Related]
34. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.
Winkler DG; Faia KL; DiNitto JP; Ali JA; White KF; Brophy EE; Pink MM; Proctor JL; Lussier J; Martin CM; Hoyt JG; Tillotson B; Murphy EL; Lim AR; Thomas BD; Macdougall JR; Ren P; Liu Y; Li LS; Jessen KA; Fritz CC; Dunbar JL; Porter JR; Rommel C; Palombella VJ; Changelian PS; Kutok JL
Chem Biol; 2013 Nov; 20(11):1364-74. PubMed ID: 24211136
[TBL] [Abstract][Full Text] [Related]
35. 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
Liu KK; Bagrodia S; Bailey S; Cheng H; Chen H; Gao L; Greasley S; Hoffman JE; Hu Q; Johnson TO; Knighton D; Liu Z; Marx MA; Nambu MD; Ninkovic S; Pascual B; Rafidi K; Rodgers CM; Smith GL; Sun S; Wang H; Yang A; Yuan J; Zou A
Bioorg Med Chem Lett; 2010 Oct; 20(20):6096-9. PubMed ID: 20817449
[TBL] [Abstract][Full Text] [Related]
36. Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.
Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Lorenzo M; Rodríguez A; Rivero V; Martín JI; Saluste CG; Ramos-Lima F; Cendón E; Cebrián D; Aguirre E; Gomez-Casero E; Albarrán M; Alfonso P; García-Serelde B; Oyarzabal J; Rabal O; Mulero F; Gonzalez-Granda T; Link W; Fominaya J; Barbacid M; Bischoff JR; Pizcueta P; Pastor J
Bioorg Med Chem Lett; 2012 May; 22(10):3460-6. PubMed ID: 22520259
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of a novel pyrrolidinyl pyrido pyrimidinone derivative as a potent inhibitor of PI3Kα and mTOR.
Le PT; Cheng H; Ninkovic S; Plewe M; Huang X; Wang H; Bagrodia S; Sun S; Knighton DR; LaFleur Rogers CM; Pannifer A; Greasley S; Dalvie D; Zhang E
Bioorg Med Chem Lett; 2012 Aug; 22(15):5098-103. PubMed ID: 22749419
[TBL] [Abstract][Full Text] [Related]
38. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
39. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
[TBL] [Abstract][Full Text] [Related]
40. Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: exploration of effective compounds in arthritis models.
Shimizu H; Yamasaki T; Yoneda Y; Muro F; Hamada T; Yasukochi T; Tanaka S; Toki T; Yokoyama M; Morishita K; Iimura S
Bioorg Med Chem Lett; 2011 Aug; 21(15):4550-5. PubMed ID: 21705219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
